What is the appropriate levetiracetam dosing regimen, including loading and maintenance doses and renal impairment adjustments, for a patient undergoing CAR‑T cell infusion?

Levetiracetam Dosing for CAR T-Cell Therapy

For seizure prophylaxis in patients undergoing CAR T-cell infusion, start levetiracetam 500-750 mg orally every 12 hours on the day of infusion and continue for 30 days, with dose adjustments required for renal impairment. 1

Standard Dosing Regimen

Seizure Prophylaxis (CAR T-Cell Context)

The NCCN guidelines specifically recommend levetiracetam for seizure prophylaxis in CAR T-cell therapy patients, particularly for products known to cause severe neurotoxicity (axicabtagene and brexucabtagene) 1. The recommended approach is:

• Starting dose: 500-750 mg orally every 12 hours
• Initiation: Day of CAR T-cell infusion
• Duration: 30 days 1

IV Formulation (When Oral Not Feasible)

If switching to IV administration becomes necessary:

• Administration: Infuse over 15 minutes 2
• Dosing: Use equivalent total daily dose and frequency as oral formulation 2
• Do not dilute the premixed bags prior to use 2

Available IV concentrations: 500 mg/100 mL, 1000 mg/100 mL, or 1500 mg/100 mL 2

Renal Impairment Adjustments

Levetiracetam is >90% renally excreted, making dose adjustment critical in renal dysfunction. 2, 3

Dosing by Creatinine Clearance 2:

Renal Function	CrCl (mL/min)	Dose Range	Frequency
Normal	>80	500-1500 mg	Every 12 hours
Mild	50-80	500-1000 mg	Every 12 hours
Moderate	30-50	250-750 mg	Every 12 hours
Severe	<30	250-500 mg	Every 12 hours
ESRD on dialysis	—	500-1000 mg	Every 24 hours*

*Following dialysis, give supplemental dose of 250-500 mg 2

Special Considerations for Critically Ill Patients

Continuous Renal Replacement Therapy (CRRT)

If the patient requires CRRT during CAR T-cell therapy, standard renal dosing may be inadequate. CRRT removes 52-73% of total levetiracetam clearance 3:

• Recommended dose: 750-1000 mg every 12 hours 3, 4
• Loading dose consideration: 60 mg/kg (maximum 4.5 g) to achieve therapeutic levels rapidly 3
• Levetiracetam clearance during CRRT approximates that of normal renal function (GFR >90 mL/min) 3

Critical pitfall: Using reduced doses based solely on renal failure without accounting for CRRT clearance results in prolonged subtherapeutic concentrations in >50% of patients 3

Augmented Renal Clearance (ARC)

Some critically ill patients paradoxically have enhanced renal clearance (CrCl >130 mL/min/1.73 m²):

• Standard 500 mg twice daily is inadequate 5, 6
• Recommended starting dose: At least 1500 mg every 12 hours 5, 6
• ARC prevalence in critically ill patients: 30-90% 5, 6

Loading Dose Strategy

While not explicitly mentioned in CAR T-cell guidelines, a loading dose of 60 mg/kg (maximum 4.5 g) significantly reduces time to therapeutic concentrations in critically ill patients requiring rapid seizure control 3. This may be particularly relevant for patients developing grade 3-4 ICANS with seizures.

Key Clinical Pitfalls

1. Underestimating CRRT clearance: Do not reduce doses excessively in patients on CRRT—they often need doses equivalent to normal renal function 3, 7

2. Missing ARC: Critically ill CAR T-cell patients may have enhanced renal clearance requiring higher doses 5, 6

3. Delayed therapeutic levels: Without loading doses, patients may remain subtherapeutic for 48-72 hours 3

4. Hepatic dysfunction: Patients with Child-Pugh class C cirrhosis on CRRT require lower doses (500-750 mg every 12 hours) due to reduced non-renal clearance 4

Monitoring Recommendations

• Monitor creatinine clearance closely, as it directly correlates with levetiracetam elimination 2, 3
• Consider therapeutic drug monitoring (target trough: 12-46 mcg/mL) in complex cases 3
• Reassess dosing if renal function changes significantly during CAR T-cell therapy course